Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23783375 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNASLC6A9SMN1; SMN2 | |
| SCHEMBL23538624 | 0.87 | SLC6A9 (0.42) | ALDH1A1MAPTLMNASLC6A9SMN1; SMN2 | |
| SCHEMBL29744740 | 0.87 | SLC6A9 (0.42) | ALDH1A1MAPTLMNASLC6A9SMN1; SMN2 | |
| SCHEMBL993182 | 0.87 | LMNA (0.65) | ALDH1A1MAPTLMNASLC6A9SMN1; SMN2 | |
| SCHEMBL30890284 | 0.87 | LMNA (0.65) | ALDH1A1MAPTLMNASLC6A9SMN1; SMN2 | |
| Lithium SCHEMBL29946996 | 0.86 | SLC6A9 (0.42) | ALDH1A1MAPTLMNASLC6A9SMN1; SMN2 | |
| SCHEMBL23783397 | 0.85 | NR1H2 (0.41) | MAPTSMN1; SMN2 | |
| SCHEMBL30207588 | 0.85 | NR1H2 (0.41) | MAPTSMN1; SMN2 | |
| SCHEMBL13419584 | 0.83 | ALDH1A1 (0.60) | ALDH1A1MAPTLMNASLC6A9SMN1; SMN2 | |
| SCHEMBL23538488 | 0.82 | SLC6A9 (0.46) | ALDH1A1MAPTLMNASLC6A9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |